Literature DB >> 12598789

Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis.

Jesús Oliva, Santiago Moreno, Jesús Sanz, Esteban Ribera, José A O Molina, Rafael Rubio, Esperanza Casas, Ana Mariño.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12598789     DOI： 10.1097/00002030-200303070-00024

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  9 in total

1.  Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy.

Authors:  C Padmapriyadarsini; P K Bhavani; Alice Tang; Hemanth Kumar; C Ponnuraja; G Narendran; Elizabeth Hannah; C Ramesh; C Chandrasekar; Christine Wanke; Soumya Swaminathan
Journal:  Int J Infect Dis       Date:  2013-09-13       Impact factor: 3.623

2.  Evaluation of antiretroviral therapy results in Blantyre, Malawi.

Authors:  J J van Oosterhout; N Bodasing; J J Kumwenda; C Nyirenda; J Mallewa; P R Cleary; M P de Baar; R Schuurman; D M Burger; E E Zijlstra
Journal:  Malawi Med J       Date:  2005-12       Impact factor: 0.875

Review 3.  Tuberculosis and HIV co-infection: a practical therapeutic approach.

Authors:  Ronan A M Breen; Leonie Swaden; Jayne Ballinger; Marc C I Lipman
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 4.  Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all.

Authors:  Awewura Kwara; Geetha Ramachandran; Soumya Swaminathan
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-01       Impact factor: 4.481

5.  Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana.

Authors:  L K Shipton; C W Wester; S Stock; N Ndwapi; T Gaolathe; I Thior; A Avalos; H J Moffat; J J Mboya; E Widenfelt; M Essex; M D Hughes; R L Shapiro
Journal:  Int J Tuberc Lung Dis       Date:  2009-03       Impact factor: 2.373

6.  AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus.

Authors:  Hadija H Semvua; Gibson S Kibiki
Journal:  BMC Res Notes       Date:  2011-11-24

7.  Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 > or = 50 cells/mm3.

Authors:  Weerawat Manosuthi; Sukanya Chimsuntorn; Sirirat Likanonsakul; Somnuek Sungkanuparph
Journal:  AIDS Res Ther       Date:  2007-03-13       Impact factor: 2.250

8.  Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: a 144-week prospective study.

Authors:  Weerawat Manosuthi; Preecha Tantanathip; Wisit Prasithisirikul; Sirirat Likanonsakul; Somnuek Sungkanuparph
Journal:  BMC Infect Dis       Date:  2008-10-14       Impact factor: 3.090

9.  Efficacy and safety of anti-tuberculosis drugs in HIV-positive patients: a prospective study.

Authors:  Jigar D Kapadia; Chetna K Desai; Manish N Solanki; Asha N Shah; R K Dikshit
Journal:  Indian J Pharmacol       Date:  2013 Sep-Oct       Impact factor: 1.200
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.